Latest Alkaloids Stories
HUNTSVILLE, Ala., Feb. 2, 2011 /PRNewswire/ -- EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product.
A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.
After a spinal cord injury a number of factors impede the regeneration of nerve cells.
CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
The relationship between smoking and cancer is well established.
SAN DIEGO, Dec.
BRIDGEWATER, N.J., Dec.
CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study.
Scientists from Germany, UK and Italy identify a molecular switch that leads to a sustained increase of calcium in nerve cells and plays a crucial role in the formation of memory and addictive behaviors.
CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- A young chicken: also used as a pet name for children.